ADCs have gotten very good at hitting protein targets on cancer cells. HER2, TROP2, Nectin-4, FRα. The antibody finds the target, the linker holds, the payload kills. It works.
But proteins aren’t the only things decorating the surface of a tumor cell.
Glycans are. These sugar structures coat every cell in the body, and cancer cells display distinct glycan patterns that differ from healthy tissue. It’s been one of those targets that everyone in glycobiology has talked about for years but nobody has successfully drugged with an ADC. Until now, potentially.
GlycoNex, based in New Taipei City, Taiwan, received PMDA approval in Japan to initiate a first-in-human Phase 1 trial of GNX1021, a glycan-targeting antibody-drug conjugate, in patients with advanced gastrointestinal cancers.
The multinational trial will run across Japan and Taiwan, with patient enrollment expected to begin mid-2026.
The Biotech Voyager
Early-stage biotech signals, personalized.
The signals that matter to you — contextualized and written directly to you — so you cut through the noise and immediately understand why it matters.
This matters for the ADC field because glycan targets could address a fundamental limitation. Protein expression on tumors is heterogeneous.
Some cells express the target, some don’t, and the ones that don’t survive the ADC and drive relapse. Glycan patterns tend to be more uniformly expressed across tumor populations, which could mean more consistent drug delivery and fewer escape routes.
GlycoNex isn’t a one-asset company either. They have a second program, GNX201-ADC, a protease-activated “pro-ADC” that uses proprietary “Antibody Lock” technology to mask the payload in circulation and activate it only in the tumor microenvironment.
They recently signed a collaboration with Nippon Kayaku to advance that program through preclinical development.
The ADC innovation wave keeps producing new angles. Dual payloads from CanWell and CrossBridge Bio. Conditional activation from GlycoNex. Entirely new target classes. The first generation of ADCs proved the concept. This generation is trying to solve the problems the first generation exposed.
GI cancers are a smart starting indication. They’re high unmet need, they tend to express aberrant glycan patterns, and the regulatory pathway in Japan is well-defined. If GNX1021 shows a safety and PK profile worth expanding, expect broader indications to follow.
The Biotech Voyager Podcast
Deep dives on the signals shaping early-stage biotech.
